Study Design and Participants
ONCOLOGY, DISEASE, SOLID TUMORS
NCI 7977 was a multicohort phase I study evaluating the safety and efficacy of veliparib and irinotecan. This manuscript describes the intermittent veliparib dosing cohort in combination with irinotecan. There was no biomarker preselection, and eligible patients had a history of metastatic or unresectable solid tumors of any histology for which standard curative or palliative measures did not exist or were no longer effective and for who irinotecan would be a viable therapy regimen. Eligible patients were required to have measurable disease according to the RECIST (version 1.1), an Eastern Cooperative Oncology Group (ECOG) performance score of 0–1, and adequate organ function as assessed by renal, hepatic, hematologic, and coagulation parameters (